Serum test identifies patients deriving benefit from CPIs 187 5 Table 2. Multivariate analysis of OS and PFS stratified by cohort for the pooled secondline population for test classification resistant versus not resistant (analysis 1) and test classification sensitive versus not sensitive (analysis 2). OS PFS Analysis 1 HR (95% CI) P HR (95% CI) P Test classification (vs. resistant) Not resistant 0.52 (0.37-0.74) <0.001 0.64 (0.47-0.88) 0.006 Histology (vs. adeno) Squamous 0.83 (0.54-1.28) 0.403 1.10 (0.75-1.60) 0.639 NA/other 1.10 (0.66-1.85) 0.711 1.09 (0.69-1.70) 0.718 Age (vs. ≥65) <65 1.14 (0.80-1.63) 0.455 1.27 (0.93-1.73) 0.130 Gender (vs. male) Female 0.52 (0.35-0.76) 0.001 0.69 (0.50-0.96) 0.027 PS (vs. 0) 1 1.56 (1.02-2.39) 0.040 1.37 (0.96-1.97) 0.084 2+ 3.66 (2.00-6.67) <0.001 2.30 (1.31-4.06) 0.004 NA 2.29 (1.15-4.54) 0.018 1.90 (1.05-3.46) 0.035 Smoking (vs. ever) Never 1.87 (0.96-3.64) 0.064 1.47 (0.81-2.67) 0.209 NA 0.76 (0.30-1.92) 0.559 0.76 (0.33-1.76) 0.521 PD-L1 (vs. positive) Negative 1.20 (0.74-1.94) 0.461 1.31 (0.85-2.03) 0.218 NA 0.84 (0.52-1.36) 0.474 0.86 (0.57-1.30) 0.476 Analysis 2 HR (95% CI) P HR (95% CI) P Test classification (vs. not sensitive) Sensitive 0.58 (0.38-0.87) 0.009 0.73 (0.51-1.04) 0.079 Histology (vs. adeno) Squamous 0.84 (0.54-1.30) 0.428 1.12 (0.76-1.63) 0.573 NA/other 1.13 (0.68-1.87) 0.648 1.10 (0.70-1.71) 0.683 Age (vs. ≥65) <65 1.06 (0.75-1.51) 0.750 1.21 (0.89-1.65) 0.227 Gender (vs. male) Female 0.49 (0.33-0.72) <0.001 0.66 (0.47-0.91) 0.011 PS (vs. 0) 1 1.41 (0.92-2.17) 0.116 1.32 (0.92-1.90) 0.136 2+ 3.31 (1.78-6.13) <0.001 2.19 (1.22-3.91) 0.008 NA 2.25 (1.14-4.45) 0.020 1.95 (1.07-3.55) 0.028 Smoking (vs. ever) Never 1.82 (0.93-3.57) 0.082 1.48 (0.81-2.71) 0.205 NA 0.83 (0.33-2.11) 0.693 0.84 (0.36-1.95) 0.676 PD-L1 (vs. positive) Negative 1.22 (0.75-1.98) 0.417 1.34 (0.87-2.07) 0.189 NA 0.97 (0.60-1.55) 0.882 0.94 (0.62-1.41) 0.755 Abbreviations: Adeno, adenocarcinoma; NA, not available; PS, performance status.
RkJQdWJsaXNoZXIy MTk4NDMw